Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
On Sunday, Longeveron Inc (NASDAQ:LGVN) presented Phase 2a clinical trial data and biomarker results at the Alzheimer’s Association International Conference (AAIC).
The Phase 2a CLEAR MIND trial evaluated 48 patients (36 were treated with Lomecel-B, and 12 received placebo).
The clinical trial achieved its primary safety and secondary efficacy endpoints, and the study results presented at AAIC 2024 support Lomecel-B’s therapeutic potential.
Key findings include:
In October last year, Longeveron announced topline results from the Phase 2a trial of its investigational product Lomecel-B for mild Alzheimer’s disease.
The primary endpoint of safety was met based on statistical and medical assessment. One Serious Adverse Event (SAE) was reported on each Lomecel-B treatment group and none on placebo.
Earlier this month, the company announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B for mild Alzheimer’s Disease.
Price Action: LGVN stock is up 22.10% at $4.20 during the premarket session at last check Monday.
Read Next:
Image via Shutterstock
Posted In: LGVN